Anaptysbio Inc. has signed an exclusive license agreement for Centessa Pharmaceuticals plc’s blood dendritic cell antigen 2 (BDCA-2) modulator antibody portfolio, including lead asset CBS-004 (to be renamed ANB-101) and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Inhibition of receptor-interacting serine/threonine-protein kinase 2 (RIPK2) has been previously described as a promising strategy for the treatment of inflammatory bowel disease, as RIPK2 is a key player in the signaling leading to bacterial peptidoglycan (PGN)-induced inflammation and it amplifies pro-inflammatory responses in the intestine.
Researchers from Abbvie Inc. have reported on the discovery and optimization of a series of selective tyrosine kinase 2 (TYK2) inhibitors that led to the identification of ABBV-712 as the lead compound.
Novacell Technology Inc. has identified peptides acting as N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Bristol Myers Squibb Co. has identified triazole N-linked carbamoyl cyclohexyl acids acting as lysophosphatidic acid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, cancer, transplant rejection, osteoporosis, inflammatory disorders, neuropathic pain, atherosclerosis and chronic obstructive pulmonary disease, among others.
Nuevolution A/S has synthesized bromodomain-containing protein 4 (Brd4, HUNK1) inhibitors reported to be useful for the treatment of cancer, hypoxia, fibrosis, autoimmune disease, inflammatory disorders and viral infections.
Trex Bio Inc. has announced its selection of a new development candidate, TRB-061, designed to selectively agonize TNF receptor 2 (TNFR2), a mechanism with potential across a broad range of autoimmune indications.
Instead of the two-step process that’s been the typical path for interchangeables in the U.S., Amgen Inc.’s Wezlana got a green light Oct. 31 from the FDA as both the first approved biosimilar and interchangeable to Johnson & Johnson’s inflammatory disease drug, Stelara (ustekinumab).
Peel Therapeutics believes evolutionary biology holds the key to developing new therapeutics for cancer and inflammation, a relatively unique approach in the world of biotech, but one that is bearing fruit: Its lead molecule is derived from camptothecin, a compound originating from the Chinese Happy Tree that is thought to have evolved as a plant defense mechanism, and it has progressed to a phase I dose escalation study in patients with advanced solid tumors.